Verified employee & interview reviews

ICON plc Reviews

Dublin, Ireland

4.0/ 5

2 reviews

ICON plc is a prominent global healthcare intelligence and clinical research organisation (CRO) headquartered in Dublin, Ireland. Founded in June 1990 by Dr. John Climax and Dr. Ronan Lambe, the company has grown from a small operation into one of the top three clinical research organisations in the world. ICON specializes in providing a comprehensive range of outsourced development and commercialisation services to the pharmaceutical, biotechnology, medical device, and government and public health sectors. Its services span the entire product lifecycle, from early-phase clinical trial management to post-market surveillance, regulatory consulting, and commercial positioning. The core operations of ICON are designed to accelerate the development of drugs and devices that save lives and improve the quality of life. The company operates through a multi-faceted service delivery model that includes full-service clinical trial execution—encompassing study setup, monitoring, patient operations, and site management—as well as specialized development and analytics, biostatistics, medical writing, and central laboratory services. Additionally, ICON is a leading global provider of Functional Service Provision (FSP) through its Strategic Solutions division, embedding dedicated teams directly within client businesses to manage specific clinical functions. ICON’s business model depends entirely on service revenue rather than consumer product sales, charging sponsors for project, milestone, functional, and time-and-materials work. The company's growth strategy relies heavily on winning large, long-duration programs and expanding into high-value therapeutic areas such as oncology, cardiovascular health, infectious diseases, metabolic disorders, immunology, and vaccines. To optimize global trial delivery, ICON utilizes its advanced ICONIX technological platform for trial design and monitoring, alongside innovative digital health solutions and decentralized trial models to maximize patient recruitment and retention across diverse populations. Financially, ICON is publicly traded on the NASDAQ under the ticker symbol ICLR. The company has achieved significant scale through strategic organic growth and high-profile acquisitions. Notably, in 2021, ICON completed a landmark $12 billion acquisition of competitor PRA Health Sciences, heavily solidifying its global footprint. For the fiscal period trailing into 2026, the company reported an annual revenue of approximately $8.25 billion to $8.28 billion, with a robust market capitalization and strong net business wins. Led by Chief Executive Officer Dr. Stephen Cutler, ICON employs over 41,900 people across 106 locations in 55 countries, maintaining deep operational networks across North America, Europe, and the Asia-Pacific region. The company continues to integrate cutting-edge capabilities, such as its Orbis multi-agent AI platform, to streamline operational cycle times, ensure audit-ready regulatory compliance, and deliver trusted data quality for global clinical trials.